alexa
Reach Us +1-217-403-9671
Pharmacokinetics Profi Le Of Tulathromycin In Egyptian Lactating Goats | 8277
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Pharmacokinetics profi le of Tulathromycin in Egyptian lactating goats

2nd World Congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit-2011 and International Conference on Pharmaceutics & Novel Drug Delivery Systems

Aziza M.M.Amer

Special Issue BABE-2011: Posters: JBB

DOI: 10.4172/0975-0851.1000105

Abstract
T ulathromycin is a novel long-acting semi-synthetic macrolide antibiotic of the triamilide group that is used in the treatment of respiratory diseases in cattle and pigs. Th e pharmacokinetics of tulathromycin were determined in fi ve lactating goats following single intravenous and intramuscular injections of 2.5 mg/kg BW with a 6 week interval between injections. Plasma, milk and urine concentrations of tulathromycin were determined using a microbiological assay method. Following a single intravenous injection of tulathromycin formulation, the concentration-time curves were best described by a two compartment open model. Tulathromycin had a high volume of distribution (V SS , 16.1 ? 2.0 L/kg) and was slowly cleared from the central compartment (126 ? 4 ml.kg -1 .h -1 ). Tulathromycin was detected in the milk of goats 30 minutes aft er IV injection with mean concentration of 0.15 ? 0.03 μg.ml -1 and persisted for 21 days over target MIC. Tulathromycin was detected in the urine from 0.5 to 96 hours aft er IV injection and exceeded the target MIC for 14 days hours post injection. Plasma protein binding was 22.8%. Following a single intramuscular injection of tulathromycin formulation, the maximum plasma concentration (0.73 ? 0.07 μg.ml -1 ) was reached at 0.5 hour and detectable tulathromycin concentrations were present in the plasma for up to 168 hours. Tulathromycin was rapidly absorbed (t ?ab , 0.104 ? 0.02 hour) and slowly eliminated (t 0.5β , 99.4 ? 11.2 h.) aft er IM injection. Th e calculated MRT infi nity was 166.3 ? 21.9 h and bioavailability was 95.8 ? 6.5%. Tulathromycin rapidly penetrated into milk with high C max-milk to C max-plasma ratio and AUC milk to AUC plasma ratio. Tulathromycin persisted in urine samples for 13 days post-injection.
Biography
Aziza Mahrous Amer has completed her Ph. D at the age of 26 years from Cairo University and postdoctoral studies from Cairo University. She is Professor of Pharmacology, Faculty of Veterinary Medicine Cairo University. She has published more than 50 papers in reputed journals and serving as an editorial board member of repute. The areas of reseaches are Pharmacokinetics ? Pharmacodynamics Pharmacokinetic interactions, Evaluation of new drug of plants and natural origin.
Top